Form 4: BioLife Solutions Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, sold 252 shares of common stock at $27.2 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, executed a sale of 252 shares of common stock on November 26, 2024.
- The shares were sold at a price of $27.2 per share.
- This transaction was conducted under a pre-existing Rule 10b5-1 trading plan adopted on February 24, 2022.
- The sale was intended to cover tax withholding obligations related to the vesting of restricted stock.
- Following the transaction, Ms. Foster directly owns 156,973 shares of BioLife Solutions common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction under a pre-existing trading plan, indicating a neutral sentiment. It is not indicative of any positive or negative outlook for the company.
Industry Context
This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without violating insider trading laws.
- The sale of 252 shares is a relatively small transaction and is not unusual for executives managing their personal finances and tax obligations.
- Similar filings are common across the biotechnology and life sciences industry, with executives regularly selling shares for various reasons including tax obligations and portfolio diversification.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on shareholder sentiment, but it is not expected to significantly affect the company's stock price due to the small volume and pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 02/24/2022 | Date the Rule 10b5-1 trading plan was adopted by Karen A. Foster. |
| 11/26/2024 | Date of the stock sale transaction. |
| 11/29/2024 | Date the Form 4 was signed. |
Keywords
BioLife Solutions, BLFS, insider trading, Form 4, Rule 10b5-1, stock sale, executive, Karen A. Foster, share transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.